Annual Meeting Proceedings, Part 2American Society of Clinical Oncology, 2009 |
Other editions - View all
Common terms and phrases
2318 Mill Road adjuvant analysis ASCO assessed AstraZeneca ax RT Background bevacizumab BrCa breast cancer Cancer Center Cancer Institute Cancer Oral Presentation carboplatin cell lung cancer chemotherapy Childhood Cancer Survivor Clinical Oncology clinical trial colonoscopy Colorectal compared Conclusions cycles CYP2D6 inhibitor disease efficacy Eli Lilly ELPAC FIGO free survival gemcitabine Genentech Gynecologic Cancer hazard ratio HD IL-2 Hospital IMRT KRAS LDCT Lilly and Company lung cancer matter under consideration median follow-up Median PFS melanoma metastatic Methods mFF6 mg bd mg/m² micrometastases months MSH2 multicenter Netherlands non-small cell lung NSCLC Odds Ratio olaparib Oncology ovarian cancer overall survival oxaliplatin paclitaxel patients pts phase III study phase III trial placebo Plenary pN1mi(sn primary endpoint primary tumor pts received PTSD radiotherapy regional recurrence relapse Research Results risk screening significantly Society of Clinical stage survival PFS tamoxifen therapy TNBC toxicity treatment vandetanib versus xerostomia